以下は学会発表でのスライド。
発症7日以内を対象にMolnupiravir 200mgの1日2回、5日内服とプラセボを比較。
鼻咽頭スワブのウイルスはday 5で47例全例が消失という結果。
REDUCTION IN INFECTIOUS SARS-CoV-2 IN TREATMENT STUDY OF COVID-19 WITH MOLNUPIRAVIR natap.org/2021/CROI/croi…
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19 businesswire.com/news/home/2021…
• • •
Missing some Tweet in this thread? You can try to
force a refresh